CMS and FDA are both working to accelerate innovation in the biosimilars market – CMS has taken action to do so by providing biosimilars with separate payment codes and by lowering the amount of cost sharing that low-income beneficiaries pay for biosimilars.
Today, the Medicare Board of Trustees released their annual report for Medicare’s two separate trust funds -- the Hospital Insurance (HI) Trust Fund and the Supplementary Medical Insurance (SMI) Trust Fund.
Centers for Medicare & Medicaid Services Administrator Mark B. McClellan, M.D., Ph.D. today announced a new CMS initiative and a proposed regulation to protect the nation’s largest federal health programs from fraud and abuse and further reduce improper payments through the use of enhanced electronic tools now available.
The Centers for Medicare & Medicaid Services welcomes the advance draft model Guidelines from the US Pharmacopeia (USP). We appreciate the hard work that went into this draft, as well as USP’s commitment to getting input from all interested parties as they work to finalize their guidelines.